Connect with us

Technology

What SCOTUS just did to net neutrality, the right to repair, the environment, and more

Published

on

What SCOTUS just did to net neutrality, the right to repair, the environment, and more

Since the New Deal era, the bulk of the functioning US government is the administrative state — think the acronym soup of agencies like the EPA, FCC, FTC, FDA, and so on. Even when Capitol Hill is not mired in deep dysfunction, the speed at which Congress and the courts operate no longer seems suitable for modern life. Both industry and ordinary people look to the administrative state, rather than legislators, for an immediate answer to their problems. And since 1984, the administrative state largely ran on one Supreme Court precedent: Chevron USA, Inc. v. Natural Resources Defense Council (NRDC). 

That decision has now been overturned. Admin law is not always interesting, but the simple fact is when it comes to the day-to-day, agencies are the most impactful part of the federal government. No single policy writer at The Verge can fully articulate the impact of Friday’s Supreme Court decision and how profound its effects will be. The administrative state touches everything around us: net neutrality, climate change, clean air and water, and what scant consumer protections we have. 

The true scope of this ruling will not be immediately felt, and what replaces Chevron deference is still unclear. The regulatory state has been under steady attack from an increasingly conservative judiciary for a long time. Some of the agencies we follow most closely were kneecapped even before this decision — one expert we talked to said that Chevron had been a “dead letter for quite some time.”

Still, this is a formal turning point. The biggest policy stories at The Verge have centered around federal agencies. And for a long time, the kind of regulation that actually kept up with the pace of technology was mostly coming out of agencies. It is in the years to come that we will wonder, “Why isn’t anyone doing anything?” or “How can a court just unilaterally do that?” about issues that range from trivial to life-threatening. 

We’ll look back on this moment as a pivotal part of how we got there.

Advertisement

What is Chevron deference?

It is a longstanding doctrine in which courts defer to federal agencies when there are disputes over how to interpret ambiguous language in legislation passed by Congress. The underlying reasoning is that subject matter experts within the agency are probably able to make more informed decisions than a judge recently assigned to the case. Chevron deference is strong deference — and the low bar for deferring to agencies means that regulations tend not to get tied up in court. 

“The key point of Chevron was that laws like these are policy decisions, and those policy decisions should be made by the political branches responsive to the voters, Congress and the president, not by unaccountable judges with no constituents,” David Doniger, an attorney and senior advisor to the NRDC Action Fund, said in a press briefing earlier this month. Doniger happened to litigate and lose the case that gave Chevron deference its name. 

While the practice had been in place for decades before, it came to be known as Chevron deference after a 1984 case: Chevron v. NRDC. The Supreme Court ruled in favor of Chevron, allowing the Ronald Reagan administration’s industry-friendly Environmental Protection Agency to stick with a lax interpretation of the Clean Air Act.

Over the years, Chevron deference has enabled federal agencies to tackle all sorts of issues that legislators have yet to cover — from addressing greenhouse gas emissions causing climate change to regulating broadband access. As the conservative legal movement to disempower the administrative state grew, Chevron deference became — in certain circles — shorthand for government overreach.

Advertisement

Before its decision to overturn Chevron, the Supreme Court had already dealt a blow to federal agencies’ regulatory authority by strengthening the “major questions” doctrine in its 2022 decision in West Virginia v. EPA. According to the major questions doctrine, a federal agency shouldn’t have the leeway to craft regulation on an issue of major national significance if Congress hasn’t explicitly allowed it to do so in legislation. 

When two cases calling for an end to Chevron deference worked their way up to SCOTUS, the writing was on the wall

The same bloc of six conservative justices that formed the majority in West Virginia v. EPA also overturned the longstanding precedent of Roe v. Wade — an even older case than Chevron — in the same month. When two cases calling for an end to Chevron deference worked their way up to the Supreme Court this year, the writing was on the wall — and once again, those same six justices overturned Chevron

Loper Bright Enterprises v. Raimondo and Relentless, Inc. v. Department of Commerce were factually about an agency rule on fishing boats, but everyone more or less knew that Chevron was on the line. The cases garnered support from a broad swath of industry interests, including Gun Owners of America and e-cigarette companies. 

Legal commentator Matt Ford wrote earlier this year that this interplay between the judiciary and industry was hardly an open secret, quoting Don McGahn — who would eventually become Trump’s White House counsel — at CPAC 2018 saying outright that “the judicial selection and the deregulatory effort are really the flip side of the same coin.”    

Advertisement

It’s not yet certain what has replaced Chevron, though some of the wording in the decision suggests we may fall back on a doctrine known as Skidmore deference — a weaker deference, meaning that judges have more power to block agency rules. “The idea that Skidmore is going to be a backup once you get rid of Chevron, that Skidmore means anything other than nothing, Skidmore has always meant nothing,” Justice Elena Kagan said during oral arguments in January.

The new threat to net neutrality

The Federal Communications Commission has famously interpreted Title II of the Communications Act to regulate internet service providers as common carriers in a policy known as net neutrality. Reclassifying ISPs as telecommunications services, rather than information services, would let the FCC impose more regulations on the industry, including mandating that they can’t unfairly block or throttle internet traffic. The idea is to keep ISPs from controlling what information users do or don’t see on the internet. In its latest move to restore the rules, the FCC said reclassifying ISPs as common carriers would also give the agency more oversight over internet outages and help it better secure internet infrastructure.

That interpretation could come under threat, even as the FCC just recently voted to reinstate net neutrality after it was repealed during the Trump administration. “Overruling Chevron has the potential to change the tenor of the impending judicial challenge to the new net neutrality rules dramatically,” University of Pennsylvania Carey Law School professor Christopher Yoo wrote in an article published prior to the Supreme Court ruling. That’s in part because prior judicial review relevant to net neutrality has taken Chevron deference into consideration. 

For example, even when the FCC previously chose to classify ISPs in a way that would lead to lighter-touch regulation, the Supreme Court ruled in National Cable & Telecommunications Association v. Brand X Internet Services that Chevron deference should be applied to the FCC’s interpretation of the Communications Act. “Brand X’s conclusion that the statute at issue is ambiguous made it highly likely that reviewing courts applying Chevron would uphold the net neutrality rules under review regardless of whether they were regulatory or deregulatory,” Yoo wrote.

Advertisement

The downfall of Chevron deference could completely change the ways courts review net neutrality, according to Bloomberg Intelligence’s Matt Schettenhelm. “The FCC’s 2024 effort to reinstitute federal broadband regulation is the latest chapter in a long-running regulatory saga, yet we think the demise of deference will change its course in a fundamental way,” he wrote in a recent report. “This time, we don’t expect the FCC to prevail in court as it did in 2016.” Schettenhelm estimated an 80 percent chance of the FCC’s newest net neutrality order being blocked or overturned in the absence of Chevron deference.

There’s still some hope at the appeals level that the FCC could successfully argue that its interpretation of its authority to regulate broadband is the best way to read the law. But Schettenhelm told The Verge it will be a “tough sell” to a conservative and business-friendly Supreme Court, which could make the final call on net neutrality.

After the opinion came out, the Information Technology and Innovation Foundation (ITIF), a think tank that receives funding from ISPs including AT&T, Comcast, and Verizon, cheered the decision and said it makes it “even less likely that the FCC’s recent regulatory overreaches on Digital Discrimination and Title II for the Internet will survive judicial review.” ITIF said the FCC’s November 2023 digital discrimination order — which allows the agency to fine telecom companies when they fail to provide equal connectivity to different groups without a good reason — could also be in danger. “Now, the Commission will no longer have the refuge of statutory ambiguity to shield this overreach from judicial scrutiny,” ITIF director of broadband and spectrum policy Joe Kane said in a statement.

What will happen to the environment and efforts to fight climate change

“It’s no coincidence that Chevron itself was an environmental case … especially for an agency like the Environmental Protection Agency that makes these highly technical, highly scientifically based decisions under very, very complicated statutes. Chevron was very important,” Lisa Heinzerling, a professor of law at the Georgetown University Law Center, said in a call with The Verge prior to today’s opinion. 

Advertisement

Overruling Chevron is essentially a big power grab, experts tell The Verge. It pushes the agency’s technical experts to the side when it comes to crafting environmental protections. In recent years, the conservative-leaning Supreme Court had already whittled down the agency’s regulatory authority — notably, by strengthening the major questions doctrine that Heinzerling describes as “the anti-Chevron.”

As a result, the EPA has already pivoted away from relying on Chevron deference, according to NRDC Action Fund’s Doniger. A rule the EPA finalized in April for cutting greenhouse gas emissions from power plants is a prime example. The Supreme Court decision in West Virginia v. EPA not only strengthened the major questions doctrine, it also said that the EPA’s rules shouldn’t determine whether utilities use fossil fuels or renewable energy. That effectively pushed the EPA to turn to controversial technologies that capture carbon dioxide from power plants in its policy to cut greenhouse gas emissions. 

The EPA wrote the rule in a way that anticipated the fall of Chevron so that it can withstand legal challenges, Doniger said in a call with The Verge. But even with the EPA’s preemptively defensive crouch, its power plant rule “is incredibly legally vulnerable” to a rollback of Chevron deference, former Trump administration EPA administrator Andrew Wheeler said in a May episode of the Politico Energy podcast. 

“The overall pattern here is clear — it’s not just in this decision — the court majority is on a rampage designed to make it harder for the government to protect us,” Doniger said. 

What happens to the push to regulate Big Tech

Advertisement

Federal Trade Commission Chair Lina Khan has made no secret of her ambitions to use the agency’s authority to take bold action to restore competition to digital markets and protect consumers. But with Chevron being overturned amid a broader movement undermining agency authority without clear direction from Congress, Schettenhelm said, “it’s about the worst possible time for the FTC to be claiming novel rulemaking power to address unfair competition issues in a way that it never has before.”

Khan’s methods have drawn intense criticism from the business community, most recently with the agency’s labor-friendly rulemaking banning noncompete agreements in employment contracts. That action relies on the FTC’s interpretation of its authority to allow it to take action in this area — the kind of thing that brings up questions about agency deference. 

But the FTC has already had to contend with trends cutting away at agency deference for quite some time. For example, the noncompete rulemaking is already facing scrutiny under the Major Questions Doctrine, which is cited in the US Chamber of Commerce’s challenge. It’s a principle that’s shown up in Supreme Court cases that basically says Congress must grant clear authority for questions of great political or economic significance. The chamber argues in its lawsuit to block the FTC noncompete rule that the Supreme Court has invoked the Major Questions Doctrine “to reject similar attempts by administrative agencies to take unprecedented actions with vast economic and political significance based on nothing more than ambiguous and ancillary statutory text—particularly where the agency has never before pointed to that text as a font of regulatory power.”

“The Supreme Court has taken most of the wind out of the sails of Chevron with the Major Questions Doctrine, in the sense that when an agency enters into a regulatory area that it hasn’t been in before, the Supreme Court has created a strong presumption the agency does not have the authority to regulate,” said Jack Beermann, an administrative law expert and professor at Boston University School of Law. “And so Chevron doesn’t enter into the picture in cases like that.”

David Vladeck, a professor at Georgetown Law who led the FTC Bureau of Consumer Protection from 2009 to 2012, said that “courts started to back off of Chevron” during the Obama administration, decreasing the utility of citing it as a defense. “As a result, lawyers like myself who were representing agencies would not rely on Chevron, and generally wouldn’t cite it because it wasn’t going to change the balance of the case. But it may signal that you need this deference in order to prevail.” Because of that, the overruling of Chevron could have a more muted impact on an agency like the FTC because “by and large, Chevron has been a dead letter for quite some time,” Vladeck said.

Advertisement

Still, there are some areas where it could come into play or exacerbate existing trends. For example, Khan has sought to enforce Section 5 of the FTC Act, governing “unfair methods of competition,” more expansively than in the past. It’s often cited in antitrust cases alongside other federal statutes like the Sherman Act. But in 2022, the FTC released a policy statement saying it could bring enforcement matters under Section 5 on a standalone basis and that authority under the statute goes beyond that of the other federal antitrust laws. Under Chevron, “the agency could rely on deference to their interpretation in order to say what constitutes an unfair method of competition,” said Ryan Quillian, a partner at Covington who served as deputy director of the FTC’s Technology Enforcement Division from 2020 to 2022. But with Friday’s decision, Quillian said, that effort “could be in jeopardy.”

Tech workers on visas and immigration law 

With regards to immigration, Chevron deference has given the Department of Homeland Security and its component agencies broad latitude. For example, under Chevron, decisions made by US Citizenship and Immigration Services (USCIS) — the federal agency that, among other things, issues non-immigrant, work-based visas like H-1Bs — were more difficult to challenge because of the requirement that courts defer to federal agencies. Tech companies rely heavily on H-1B workers. Nine of the 10 companies that filed the most H-1B petitions during the 2022 fiscal year —including Amazon, Google, and Meta — were in the tech sector, according to federal data analyzed by the Economic Policy Institute. 

“In the past, employers have had a hard time overturning narrow interpretations of H-1B issues because of Chevron deference,” Stephen Yale-Loehr, a professor of immigration law practice at Cornell Law School, told The Verge. “Now, however, people who feel that the agency is too stingy in its interpretation of various visa categories may be more likely to seek court review.”

The desire to seek court review, however, will likely depend on an applicant’s location. Jonathan Wasden, a former government attorney whose firm, Wasden Banias, specializes in visa cases, said the overturning of Chevron will likely create a patchwork system. “I was hoping for them to create a framework, but right now it’s really in the eye of the particular judge that’s reviewing your case — which is great if you’re a litigant and an agency is acting silly, but for the government, it’s going to be a big problem,” Wasden told The Verge. “You’re looking at 96 federal courts with all different views of how the statute is supposed to work.”

Advertisement

Going forward, instead of relying on a single framework across the country, USCIS will likely pay more attention to where an applicant is located to determine how statutes will apply to them. “For an agency that already is challenged, it’s going to be tough, because they’re just not that nimble,” Wasden said. 

In other words, the amount of recourse available to a person whose H-1B petition is denied by USCIS will depend largely on their location. predicts that the biggest challenge for the government will be in “as applied” cases, or those that argue that the application of a particular statute or policy — and not the statute or policy itself — is unconstitutional. “There’s going to be a lot of individual litigants with compelling facts across the country on the exact same issue, and we’re going to see a variety of ways to resolve and interpret the law in those cases,” Wasden said.

The effects of this patchwork system will not be felt immediately, nor will they be felt evenly. “A lot needs to be worked out,” said Yale-Loehr, “and it will be confusing and complicated for several years.“

Labor and workers’ rights

The overturning of Chevron may make it easier to challenge policies implemented by labor agencies going forward, including efforts to enact workplace safety regulations. The Biden administration has implemented a number of regulations related to workplace safety and worker treatment. This year alone, the Department of Labor extended overtime pay to workers making below $58,656, announced a regulation allowing third parties on worksite inspections, and the Equal Employment Opportunity Commission issued new guidance on workplace harassment for the first time since 1999. The regulation raising the salary threshold for overtime pay, slated to go into effect on July 1st, faces multiple legal challenges from industry groups.

Advertisement

In an email to The Verge, Charlotte Garden, a professor of labor law at the University of Minnesota, said the decision to overturn Chevron will likely be “disruptive for workers’ rights.”

“The DOL’s long-standing approach to whether an employee is ‘exempt’ from overtime under the ‘white-collar’ exemption involves looking at both the amount of the employee’s salary, and their duties — so employees are entitled to overtime pay unless they earn more than the salary threshold and perform qualifying duties,” Garden said. Business groups have argued that the DOL “isn’t allowed to set a salary threshold at all” — an argument Garden said is more likely to win now that Chevron is overturned. 

“Under Chevron, if a judge thought the [Fair Labor Standards Act] was ambiguous, it would then defer to the DOL’s reasonable interpretation of that statute,” Garden said. “But now, judges are free to decide what they think the best reading is.” As is the case with immigration, different judges will reach different decisions about how to interpret regulations, which could lead to different regulatory schemes across the country.

Under Biden, the Occupational Safety and Health Administration (OSHA) has been working on heat stress regulations intended to protect workers from increasingly high temperatures on the job — a proposal that has already faced pushback.

“It’s much harder for an agency to take big swings when it’s regulatory authority when it’s not going to get a layup when it goes into defendant,” Alexander MacDonald, a shareholder at Littler’s Workplace Policy Institute, told The Verge.

Advertisement

Michael Rubin, a partner with the public interest firm Altshuler Berzon, said the success of these challenges remains to be seen. “They still have to go through the same procedures for challenging it: a challenge goes to court, and it simply means that the courts will take a de novo — fresh look — at the statute,” said Rubin, whose firm has represented gig worker drivers and Apple employees who recently filed a gender discrimination lawsuit against the company. More consequential, Rubin adds, is the fact that the Supreme Court is divided on how to construe statutes and constitutional provisions. “There’s likely to be far more litigation, without the benefit of Chevron deference, resulting in greater uncertainties, greater delays, and more inefficient practices throughout the country,” Rubin said. “It’s going to put an enormous burden on Congress and the courts, as well as the agencies, and it will certainly take months — if not years — to determine the actual impact.”

The right to repair, copyright, patent law, and the Apple Watch ban 

Intellectual property issues will probably see the least impact and almost certainly the lowest body count, but the fact that Chevron deference is applicable to any of these issues at all may be illustrative of the sheer scope of the administrative state. 

In 2015, an appeals court applied Chevron to the US International Trade Commission. The ITC does many things, but you likely last heard about it in 2023 when it ruled that the Apple Watch infringed on patents for pulse oximetry, resulting in a temporary ban for imports of the Apple Watch. “I do think the demise of Chevron will affect patent law, though I agree most folks will have bigger fish to fry,” Mark Lemley, a professor at Stanford Law School, wrote in an email to The Verge. “The ITC would presumably not be entitled to deference in its interpretation of patent law.”

In 2017, an appeals court — controversially — applied Chevron to the Patent and Trademark Office’s interpretation of patent law. “The PTO makes few substantive rules,” Rebecca Tushnet, a professor at Harvard Law School, wrote in an email. The less agency rulemaking, the less impact overturning Chevron will have. 

Advertisement

But there is one notable part of intellectual property law where agency rulemaking matters quite a lot and happens in bulk: every three years, the Copyright Office issues exemptions for DMCA Section 1201. These cover the right to repair, unlocking cellphones, ripping DVDs for archival or educational purposes, taking apart electronic voting machines to test for security issues, and more. The Copyright Office falls under the legislative branch, rather than the executive, where admin law traditionally applies. But earlier in June, an appeals court ruled these DMCA rulemakings were subject to the Administrative Procedure Act, the 1946 statute from which Chevron, Loper Bright, and the entire administrative state stems. These DMCA rulemakings are already contentious, even when enclosed in the usually boring notice-and-comment process — but the combination of this ruling and the death of Chevron may have the recurring triennial conflict sprawling into the courts as well. 

To be clear, none of these are necessarily bad outcomes — and as Lemley notes, most people “have bigger fish to fry.” No one is going to think, Well, on the one hand climate change will kill us all, but on the other hand, I have my Apple Watch.

Beyond that, the disempowering of federal agencies means the empowerment of another entity — and in this case, it is the increasingly conservative judiciary. Article III courts do not always make the best decisions, even when it comes to relatively apolitical issues like software copyright. This shift in the balance of power will touch on issues both big and small, dire and inane in the years to come.  

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Technology

Honda’s hybrid future starts with new Accord and RDX prototypes

Published

on

Honda’s hybrid future starts with new Accord and RDX prototypes

Honda revealed prototypes of two new hybrid models, an Accord sedan and the Acura RDX SUV, during its annual business briefing this week, built on a platform that it says will begin launching next year. The RDX was announced earlier this year as Honda’s first SUV to feature the next-gen version of its two-motor hybrid system.

In March, Honda announced it would take a writedown of up to 2.5 trillion yen ($15.7 billion) on its EV investments. Now Honda says its EV-related losses will be “resolved” by 2029, and that it will reevaluate its EV plans in 2030.

Continue Reading

Technology

New cancer tech sends chemo straight to tumors

Published

on

New cancer tech sends chemo straight to tumors

NEWYou can now listen to Fox News articles!

Chemotherapy can save lives, but anyone who has watched a loved one go through it knows how hard it can be. The nausea. The exhaustion. The infections. The days when even getting off the couch feels like too much.

That happens because standard chemotherapy travels through the bloodstream. It attacks cancer cells but can also harm healthy cells along the way. For some pancreatic cancer patients, that approach may be changing.

A targeted drug-delivery system from RenovoRx is designed to send chemotherapy directly near the tumor instead of through the entire body. The system, called Trans-Arterial Micro-Perfusion, or TAMP, is being studied in a Phase III clinical trial for locally advanced pancreatic cancer.

For 83-year-old Hernando Salcedo, who had been left weak, nauseous and overwhelmed by standard chemotherapy, the trial offered something he desperately needed: a reason to hope. He enrolled at Miami Cancer Institute and soon began to feel the shift in his own body. His appetite started coming back. His energy improved. He felt more like himself. “The difference was tremendous,” Hernando said. “I completed eight sessions, one every 15 days, and I felt dramatically better than I did with the original chemotherapy.”

Advertisement

HIDDEN FACTOR IN CANCER TREATMENT TIMING MAY AFFECT SURVIVAL, RESEARCHERS SAY

Cancer patient Hernando Salcedo attended a family wedding after RenovoRx’s Trans-Arterial Micro-Perfusion system delivered chemotherapy directly near his tumor, helping him feel stronger during treatment. (Hernando Salcedo)

 Sign up for my FREE CyberGuy Report

  • Get my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox.
  • For simple, real-world ways to spot scams early and stay protected, visit CyberGuy.com trusted by millions who watch CyberGuy on TV daily.
  • Plus, you’ll get instant access to my Ultimate Scam Survival Guide free when you join.

 

How the RenovoRx drug-delivery device works

RenovoRx’s platform uses the FDA-cleared RenovoCath device to deliver chemotherapy through a catheter placed in an artery near the tumor. A physician guides the catheter into position using X-ray imaging.

Shaun Bagai, CEO of RenovoRx, said the platform is designed to localize chemotherapy delivery near the tumor instead of relying on the drug to travel through the whole body.

“Once in position, two small balloons on the catheter are inflated, and the system is adjusted to isolate a targeted segment of artery adjacent to a tumor,” Bagai said. “The chemotherapy drug is then infused between the balloons, creating pressure to push the drug across the vessel wall and near the tumor, directly bathing the target tumor.”

Advertisement

That setup allows doctors to focus treatment in a specific area rather than exposing more of the body to chemotherapy. “The procedure itself is minimally invasive and is typically performed in an outpatient setting without the need for patients to be put under general anesthesia,” Bagai said.

For patients already dealing with pain, fatigue and fear, that outpatient approach may feel less overwhelming than a major hospital procedure.

 

How targeted chemotherapy for pancreatic cancer works

To understand why this approach matters, it helps to start with the problem doctors are trying to solve. Dr. Ripal Gandhi, a vascular interventional radiologist and interventional oncologist at Baptist Health Miami Cardiac & Vascular Institute and Miami Cancer Institute, explained why standard chemotherapy can be so hard on the body.

“With IV chemotherapy, the drug travels through the bloodstream, affecting both cancerous and healthy cells, which can lead to side effects,” Dr. Gandhi said. TAMP takes a more targeted route. A doctor places a catheter in an artery near the tumor, then delivers chemotherapy into that area instead of relying on the drug to circulate throughout the body.

Dr. Gandhi compared it to “a drip irrigation system for individual plants instead of watering an entire lawn.” For patients, that means doctors are trying to focus more of the treatment near the cancer while reducing how much chemotherapy reaches the rest of the body.

Advertisement

 

Why pancreatic cancer is so difficult to treat

Pancreatic cancer has a reputation for being one of the hardest cancers to fight, partly because the tumor itself can block treatment from working the way doctors want it to.

Dr. Gandhi said that creates a major challenge for standard IV chemotherapy. “Studies have shown that less than 10% of chemotherapy administered intravenously actually reaches tumor cells due to the few blood vessels in the tumor as well as dense fibrous stroma, which serves as a physical barrier in the tumor microenvironment,” Dr. Gandhi said.

That helps explain why targeted delivery could play an important role. TAMP sends the drug closer to the tumor rather than depending on the bloodstream to do all the work.

“This targeted approach via TAMP does not rely on chemotherapy circulating through the body to carry the drug to the tumor via tumor feeder vessels,” Dr. Gandhi said. “Trans-arterial micro-perfusion is a drug-delivery platform that delivers chemotherapy directly near the target tumor where it is needed most.”

NEW CANCER THERAPY HUNTS AND DESTROYS DEADLY TUMORS IN MAJOR BREAKTHROUGH STUDY 

Advertisement

Chase McCann, associate director of the cell therapy lab core, demonstrates how cancerous T-cells from a child are used to develop an autoimmune treatment to fight cancer at Children’s National Hospital in Washington, D.C., on Aug. 26, 2025. (Marvin Joseph/The Washington Post/Getty Images)

 

Patient says targeted chemotherapy gave him hope

Hernando’s cancer journey began after he went to the doctor with a swollen stomach and hip pain. Doctors diagnosed him with locally advanced pancreatic cancer. When he started standard chemotherapy in August 2025, the side effects hit hard. “My body was going through an incredible amount of stress,” Hernando said. “My stomach was inflamed, I had persistent pain in my head, and I had almost no energy.”

He was also receiving chemotherapy and radiation at the same time. “It was a very difficult period, both physically and emotionally,” he said. “I remember feeling exhausted, overwhelmed and unsure of what the future would look like.”

When doctors presented the targeted treatment option, Hernando saw it as more than another medical procedure. “To me, it felt like a new opportunity to live,” he said. “It gave me hope at a time when my family and I really needed it.”

He credits Dr. Gandhi and the team at Miami Cancer Institute with helping him through it all. “From the beginning, he was honest, supportive and clear with my wife, my family and me,” Hernando said. “That meant everything.” 

Advertisement

Fewer chemotherapy side effects changed daily life

“Before, I was losing weight, had no appetite and felt drained,” Hernando said. “After switching treatments, things began to change. I stopped losing weight, my appetite came back, my color improved and I had more energy.”

Cancer treatment can sometimes take over everyday life. When side effects ease, patients can get pieces of their normal life back. “After about eight weeks, we could see real progress,” Hernando said. “I was eating more, moving more and feeling excited about life again.”

One moment still stands out. Hernando was able to attend a family wedding and dance the entire night. “That moment meant everything to me,” he said. “After everything I had been through, being able to celebrate with my family in that way felt like a gift.” For Hernando, it was a chance to feel like himself again. “That night at the wedding, I was not thinking only about cancer or treatment,” Hernando said. “I was living.”

 

Early trial results show survival and quality-of-life signals

The early data from RenovoRx’s Phase III TIGeR-PaC trial suggest the targeted approach may offer both survival and tolerability benefits for some patients.

Dr. Gandhi said completed clinical studies with TAMP in pancreatic cancer showed “a potential for better outcomes and less side effects for patients.”

Advertisement

“In the initial interim analysis of the TIGeR-PaC clinical trial, there was a trend towards improved overall survival by 6 months and improvement in the progression free survival by 8.1 months with 65% fewer adverse events in the TAMP arm of the study,” Dr. Gandhi said.

 

Who may benefit from targeted chemotherapy delivery?

This approach isn’t for every pancreatic cancer patient. Doctors still need to look at the cancer stage, tumor location, treatment history and whether the cancer has spread.

Dr. Gandhi said Hernando was the kind of patient who could be a strong fit. “He is precisely the type of patient who would benefit best from this approach because he has a tumor which is too far advanced to be treated surgically, but it has not spread to other organs,” Dr. Gandhi said.

He also pointed to clinical trials as an important option for pancreatic cancer patients.”I discussed with him that the recommendation of the National Comprehensive Cancer Network is that the best management for pancreatic cancer patients is participation in a clinical trial whenever possible and he was an ideal candidate,” Dr. Gandhi said.

He went on to say that TAMP may be an option for patients who are not candidates for surgery, patients who have failed chemotherapy or patients who no longer want to continue IV chemotherapy because of side effects.

Advertisement

“TAMP can be used at any point within the treatment landscape, before, during or after other treatment modalities such as IV chemotherapy or radiation,” he said.

PANCREATIC CANCER PATIENT SURVIVAL DOUBLED WITH HIGH DOSE OF COMMON VITAMIN, STUDY FINDS

The RenovoCath device uses a catheter-based system to deliver chemotherapy near the tumor instead of through the whole body. (RenovoRx)

 

What comes next for RenovoRx’s cancer treatment platform

RenovoRx says the RenovoCath catheter is already FDA-cleared for general therapy and chemotherapy delivery. The company is also nearing the end of enrollment in its Phase III TIGeR-PaC trial.

That trial is evaluating intra-arterial gemcitabine (IAG) delivered through RenovoCath for locally advanced pancreatic cancer. Bagai said enrollment is expected to be completed in mid-2026, with final results expected in 2027.

Advertisement

“If positive, data generated from this trial could potentially support a new drug application for this combination product to the FDA for IAG,” Bagai said. RenovoRx also sees potential beyond pancreatic cancer. “The challenge we are addressing is not unique to pancreatic cancer,” Bagai said.

He said the platform could apply to other solid tumors with limited blood supply, including bile duct cancer, certain lung cancers and sarcomas. “The platform is designed to work with different types of therapies, not just one drug,” Bagai said. “That opens the door to future combinations and potential partnerships, with the goal of expanding options for patients who have limited treatment choices.” 

 

What this means to you

If you or someone you love has pancreatic cancer, this story is worth paying attention to. Clinical trials can open up options when standard treatment feels too hard to tolerate or stops working.

Drug delivery matters, too. The medicine itself is only part of the story. Where it goes inside the body can affect side effects, energy levels and quality of life. Targeted chemotherapy delivery remains a specialized treatment approach. Some cancer centers may not offer it, and every diagnosis will not be a fit. Your care team can review imaging, staging, prior treatments and overall health to see whether it makes sense.

Start with direct questions. Ask whether a clinical trial makes sense. You can also ask about targeted delivery options or a second opinion from a pancreatic cancer specialist. Hernando’s advice to other patients is simple. “I would tell them not to lose hope and not to wait to ask questions,” he said. 

Advertisement

Take my quiz: How safe is your online security?

Think your devices and data are truly protected? Take this quick quiz to see where your digital habits stand. From passwords to Wi-Fi settings, you’ll get a personalized breakdown of what you’re doing right and what needs improvement. Take my Quiz here: Cyberguy.com     

 

Kurt’s key takeaways

Pancreatic cancer has a way of turning normal life upside down fast. One day, a family is making plans. The next, they are trying to understand scans, treatment choices and side effects that no one feels ready for. That is what makes Hernando’s story so powerful. The part that stays with you isn’t only the technology. It is the fact that he started eating again. He had more energy. He felt more like himself. And he got to dance at a wedding after wondering what the future would look like. The final Phase III trial results will be important. Doctors still need to see how widely this approach could help patients. But the promise is easy to understand. If chemotherapy can get closer to the tumor while taking less of a toll on the rest of the body, patients may get something that matters just as much as treatment itself: more good days.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

If you or someone you loved needed chemo, would targeted delivery change how you think about treatment? Let us know by writing to us at Cyberguy.com

Advertisement

Sign up for my FREE CyberGuy Report

  • Get my best tech tips, urgent security alerts and exclusive deals delivered straight to your inbox.
  • For simple, real-world ways to spot scams early and stay protected, visit CyberGuy.com trusted by millions who watch CyberGuy on TV daily.
  • Plus, you’ll get instant access to my Ultimate Scam Survival Guide free when you join.

Copyright 2026 CyberGuy.com.  All rights reserved.

Continue Reading

Technology

Use this map to find the data centers in your backyard

Published

on

Use this map to find the data centers in your backyard

When Oregon resident Isabelle Reksopuro heard Google was gobbling up public land to fuel its data centers in her home state, she didn’t initially know what to believe. “There’s a lot of misinformation about data centers,” she said. “Google has denied taking that land.”

Technically, she explains, The Dalles, a city near the Washington state border, sought to reclaim that land, “and Google is just a big, unnamed power user.” The city had in fact asked for ownership of a 150-acre portion of Mount Hood National Forest, claiming it needs access to Mount Hood’s watershed to meet municipal needs as its population — 16,010 as of the 2020 census — grows. But critics, including environmentalists, say the city is trying to secure more water for Google, which has a sprawling data center campus in The Dalles that already consumes about one-third of the city’s water supply.

This controversy made Reksopuro curious about the backlash to data centers being built in other communities. So Reksopuro, a student at the University of Washington who studies the connections between tech and public policy, decided to map it out. Using information collected by Epoch AI and data scraped from legislation on data centers, she built an interactive map tracking AI policy around the world. She designed it to be simple enough for anyone to use. “I wanted it to be something that my younger sisters could play through and explore to understand what are the data centers in the area and what’s actually being done about it,” Reksopuro said. She hoped to shift their opinions that way, “instead of like, through TikTok.”

Four times a day, the map searches for new sources and checks them against the existing database Reksopuro built out. “Once it does that, it will write a new summary, add it to the news feed, and populate it on the sidebar,” she said. “I wanted it to be self-updating, since I’m also a student.”

Reksopuro isn’t against data centers, but she thinks tech giants benefit from a lack of transparency around data center policies. “Right now, it’s this really opaque thing — and all of a sudden, there’s a facility,” she said. “I think that if people knew about data centers beforehand, it would give them leverage. They would be able to negotiate: ask for job training programs, tax revenue, environmental monitoring, things to improve their community.”

Advertisement
Continue Reading
Advertisement

Trending